VWF and thrombotic thrombocytopenic purpura: Diving into the mechanistic of caplacizumab, it neutralizes ultra-large vWF multimers, preventing platelet aggregation persistence and limiting inflammatory amplification, processes that are central to TTP pathophysiology.